See more : BKV Corporation (BKV) Income Statement Analysis – Financial Results
Complete financial analysis of Gamida Cell Ltd. (GMDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gamida Cell Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MedTech Acquisition Corporation (MTACW) Income Statement Analysis – Financial Results
- Tiger Tasman Minerals Limited (T1G.AX) Income Statement Analysis – Financial Results
- China Sinostar Group Company Limited (0485.HK) Income Statement Analysis – Financial Results
- The Go-Ahead Group plc (GOG.L) Income Statement Analysis – Financial Results
- FUJIFILM Holdings Corporation (FUJIF) Income Statement Analysis – Financial Results
Gamida Cell Ltd. (GMDA)
About Gamida Cell Ltd.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.48M | 440.00K | 431.00K | 357.00K | 2.14M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.69M | -440.00K | -431.00K | -357.00K | -2.14M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -94.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 22.28M | 42.69M | 50.18M | 41.39M | 31.46M | 22.05M | 15.02M | 19.10M |
| General & Administrative | 44.58M | 19.40M | 16.98M | 12.17M | 12.09M | 11.60M | 4.47M | 4.61M |
| Selling & Marketing | 4.08M | 12.90K | 20.01K | 8.89K | 4.69K | 0.00 | 0.00 | 0.00 |
| SG&A | 48.67M | 19.40M | 16.98M | 12.17M | 12.09M | 11.60M | 4.47M | 4.61M |
| Other Expenses | -395.00K | 12.90M | 20.01M | 8.75M | 4.69M | 195.00K | -2.27M | 1.81M |
| Operating Expenses | 70.95M | 74.99M | 87.17M | 62.30M | 48.25M | 33.64M | 19.49M | 23.71M |
| Cost & Expenses | 74.43M | 74.99M | 87.17M | 62.30M | 48.25M | 33.64M | 19.49M | 23.71M |
| Interest Income | 2.73M | 4.38K | 2.63K | 236.00K | 17.15M | 1.04M | 330.00K | 163.00K |
| Interest Expense | 7.59M | 4.38M | 2.63M | 10.64M | 3.33M | 20.26M | 30.00K | 23.00K |
| Depreciation & Amortization | 2.02M | -149.55M | 431.00K | 2.63M | 19.29M | 269.00K | 162.00K | 124.00K |
| EBITDA | -70.62M | -74.55M | -86.74M | -60.57M | -28.95M | -32.60M | -20.16M | -24.48M |
| EBITDA Ratio | -3,958.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.64M | 74.99M | -87.17M | -62.30M | -48.25M | -33.64M | -19.49M | -23.71M |
| Operating Income Ratio | -4,071.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.65M | -4.38M | -2.63M | -648.00K | 13.82M | -19.22M | 479.00K | 1.04M |
| Income Before Tax | -63.00M | -79.38M | -89.79M | -72.70M | -34.42M | -52.86M | -19.01M | -22.67M |
| Income Before Tax Ratio | -3,531.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.00 | 74.99M | 2.63M | 3.74M | -70.00K | 70.00K | -479.00K | -1.04M |
| Net Income | -63.00M | -154.37M | -92.42M | -76.45M | -34.35M | -52.93M | -19.01M | -22.67M |
| Net Income Ratio | -3,531.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.57 | -2.42 | -1.56 | -1.75 | -1.17 | -10.53 | -1.06 | -1.26 |
| EPS Diluted | -0.57 | -2.42 | -1.56 | -1.75 | -1.16 | -10.53 | -1.06 | -1.26 |
| Weighted Avg Shares Out | 110.05M | 63.83M | 59.25M | 43.73M | 29.46M | 5.03M | 17.97M | 17.97M |
| Weighted Avg Shares Out (Dil) | 110.05M | 63.83M | 59.25M | 43.73M | 29.66M | 5.03M | 17.97M | 17.97M |
Why Is Gamida Cell (GMDA) Stock Down 19% Today?
Gamida Cell (NASDAQ: GMDA ) stock is falling on Wednesday after the cell therapy company revealed details of a public securities offering. According to a press release from the company, it is selling both shares of GMDA stock, as well...
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares at a...
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares at a...
Gamida Cell Announces Launch of Public Offering of Securities
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants to purchase its ordinary shares. In addition,...
Gamida Cell Announces Launch of Public Offering of Securities
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants to purchase its ordinary shares.
Gamida Cell Stock Jumps Over 100% on FDA Approval
Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight blood cancer and other illnesses.
Gamida Cell shares jump on FDA recognition of allogeneic cell therapy
Gamida Cell shares shot higher on Tuesday after its allogeneic cell therapy received US Food and Drug Administration (FDA) approval. Its drug candidate Omisirge received breakthrough therapy designation, priority review and orphan drug designation from the FDA, sending shares of...
Why Is Gamida Cell (GMDA) Stock Up 48% Today?
Gamida Cell (NASDAQ: GMDA ) stock is taking off on Tuesday after getting an update from the FDA concerning Omisirge. Omisirge is the company's cell therapy designed to treat patients with hematologic malignancies planned for umbilical cord blood transplantation after...
Promising Upsides on these Biotech Penny Stocks
For investors willing to do their research and take calculated risks, biotech penny stocks can offer the potential for high returns. These companies have a low market capitalization and are not yet profitable, but they offer the potential for high...
Gamida Cell's Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the U.S.
Source: https://incomestatements.info
Category: Stock Reports